CD8-CLA(+) T cells are reduced in peripheral blood of patients with non-segmental vitiligo. This finding may be related to the previously reported increase of CD8(+) cells in both lesions and perilesional skin of these patients.
Background: The evidence that vitiligo is an autoimmune disease is supported by its association with autoimmune conditions, the presence of activated cytotoxic T lymphocytes in the lesions and melanocyte-specific circulating auto-antibodies. Some studies have indicated the normal-appearing skin being immune-targeted for latent melanocyte disappearance. Method: We aimed to characterize immunohistologically the cellular infiltrate and to identify the distribution pattern of T and Langerhans cells (LCs) in the active border of depigmenting lesions and clinically normal skin of 22 patients with progressive non-segmental vitiligo, besides the cellular expression for the cutaneous lymphocyte-associated antigen (CLA), comparing to 10 controls. Results: Immunohistochemical analyses showed an overall reduction of the number of CD1a+ cells, dermal increase of CD8+ T cells, and increase of the epidermal CD3+ T cells number in the active border of lesions. Surprisingly, those cellular changes were also observed in clinically pigmented skin. However, a significant intra-epidermal infiltration of CD8+ T cells was evident only within active border biopsies. The CLA+ cells were not significantly increased in the patients' skin. Conclusions: The findings of this study suggest an extensively immune-committed skin in active vitiligo, mainly characterized by overall scarcity of CD1a+ cells and dermal increase of CD8+ cells even in apparently normal skin, in addition to the epidermal infiltrate of CD8+ T cells in the depigmenting areas. This report further supports that some CD8+ T and LCs cells play a pivotal role in the process of melanocyte loss, and strengthens an auto-immune hypothesis for vitiligo.
ComunicaçãoResumo: Na patogênese do vitiligo tem-se enfatizado o papel das células T citotóxicas. Identificadas pelo antígeno linfocitário cutâneo (CLA), essas células já foram descritas no sangue de pacientes com outras dermatoses e podem ser depletadas pela fototerapia concomitantemente à melhora clínica. Descreve-se caso de vitiligo generalizado com melhora clínica expressiva após Puva, no qual houve redução de 25% dos linfócitos T CD8 + -CLA + circulantes. Palavras-chave: Imunofenotipagem; Terapia Puva; Vitiligo Abstract: The role of cytotoxic T cells (CD8+) has been emphasized in the pathogenesis
No abstract
Objectives:To determine the more frequently seen clinical and immunologic manifestations in the antiphospholipid syndrome (APS) in patients of 2 referral centers. Methods: We studied 50 patients with the diagnosis of primary or secondary APS, 49 females and 1 male, with ages ranging between 15 and 65-year-old, using a predetermined protocol in which we measured the immunologic and clinical spectrum, including the determination of anticardiolipin antibodies (ACA) and lupus anticoagulant (LA); in some cases we also measured anti- 2-glycoprotein I. Results: The most frequent clinical manifestations were thromboses in several sites detected in 88% of cases; the most common location was the lower extremities (40%) and as pulmonary emboli was detected in 20%. Arthritis was found in 70% of the cases, livedo reticularis in 52%, Raynaud phenomena in 50%, migraine in 40%, hemolytic anemia in 30%, major depressive disorder in 22% and recurrent miscarriage in 18%. Immunologic studies showed antinuclear antibodies (ANA) in 80%, ACA of IgM and IgG isotypes were found in 56% and 44% respectively, LA in 34% and anti-DNA antibodies in 40%. Conclusions:The main clinical manifestations in patients with APS are: lower extremities thromboses, pulmonary emboli, cutaneous, articular and neurologic involvements, with the presence of ACA (isotype IgM). Introduction:The catastrophic antiphospholipid syndrome (CAPS) is characterized by a rapid-progressive thrombosis of small vessels, multiple organ failure in the presence of antiphospholipid antibodies, might be fatal in more than 50% of cases. The risk-factors identified in the develop of CAPS are, bacterial and/or viral infections, surgery, inadequate treatment of systemic lupus erythematosus (SLE), inadequate treatment of antiphospholipid syndrome (APS), or use of estrogens. Objectives: To identify methods to prevent the progression to CAPS in patients with primary and secondary antiphospholipid syndrome (APS). Patients: Patient 1: 28-year-old female with SLE without treatment, with a previous history of 2 fetal losses and 2 normal vaginal deliveries. During the 3rd trimester of her 5th pregnancy the patient presented with fever, hypertension, renal involvement, deep vein thrombosis, cerebral organic syndrome, convulsions and coma. Patient 2: 22-year-old female with SLE, lupus nephropathy classified as WHO class IV, secondary APS and cutaneous vasculitis. Exacerbation of the SLE was secondary to sun exposure and insufficient corticosteroids doses. Methods:The risk-factors were identified and the patients were treated with: 1. High corticosteroid doses. 2. Full anticoagulation with low molecular weight heparin. 3. Aggressive broad-spectrum antibiotic treatment. 4. Intravenous immunoglobulins infusions at the doses of 1g/kg/d for 2 subsequent days. 5. Control of the hematological disorder in the intensive care unit (ICU). Results: The outcomes of both patients were successful as demonstrated by controlling the events and not developing CAPS. Conclusions: Our experience suggests that ever...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.